Supporting Information

## Peptide Amphiphiles with Distinct Supramolecular Nanostructures for

## **Controlled Antibacterial Activities**

Ruilian Qi,<sup>†,‡</sup> Pengbo Zhang,<sup>§,‡</sup> Jian Liu,<sup>I,‡</sup> Lingyun Zhou,<sup>§,‡</sup> Chengcheng Zhou,<sup>†</sup> Na Zhang,<sup>†,‡</sup> Yuchun Han,<sup>\*,†</sup> Shu Wang,<sup>\*,§,‡</sup> and Yilin Wang<sup>\*,†,‡</sup>

<sup>†</sup>Key Laboratory of Colloid, Interface and Chemical Thermodynamics, <sup>§</sup>Key Laboratory of Organic Solids, and <sup>I</sup>Key Laboratory of Molecular Nanostructure and Nanotechnology, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China

<sup>‡</sup>University of Chinese Academy of Sciences, Beijing 100049, P. R. China

## **Experimental Section**

### Materials

Gemini-type peptide amphiphiles N<sup> $\alpha$ </sup>-dodecanoyl-lysine-lysine-O<sup> $\alpha$ </sup>-dodecylamide 12-(Lys)<sub>2</sub>-12, N<sup> $\alpha$ </sup>-dodecanoyl-lysine-lysine-lysine-lysine-O<sup> $\alpha$ </sup>-dodecylamide 12-(Lys)<sub>4</sub>-12, and N<sup> $\alpha$ </sup>dodecanoyl-lysine-lysine-lysine-lysine-lysine-O<sup> $\alpha$ </sup>-dodecylamide 12-(Lys)<sub>6</sub>-12 were synthesized through solid phase method and purified by high-performance liquid chromatography. Their structures were confirmed by <sup>1</sup>H NMR and mass spectra, and the purities are higher than 95% as checked by high performance liquid chromatography. Phosphate buffered saline (1× PBS, pH 7.4) was used throughout the work.

#### Methods

**Critical aggregate concentration (CAC) determination**: The CAC of each PA was determined from surface tension measurements on a DCAT 11 surface tensiometer (DataPhysics). Stock Solution of PA solution was progressively adding into PBS and examined by a Pt/Ir plate method at  $25.00 \pm 0.01$  °C. The CAC value was calculated by plotting the surface tension against the log of PA concentration. The measurements were repeated at least twice.

**Dynamic light scattering (DLS) measurements**: Size distributions of the aggregates formed by these PAs in PBS were measured by a Malvern Zetasizer Nano-ZS instrument equipped with a 4 mW He–Ne laser ( $\lambda = 632.8$  nm). The temperature was controlled at  $25.0 \pm 0.1$  °C using a thermostated chamber.

**Cryogenic transmission electron microscopy (Cryo-TEM)**: Samples for Cryo-TEM were prepared by pipetting 5  $\mu$ L of PA solutions onto a carbon-coated holey TEM grid, blotted and plunged into liquid ethane. The vitrified samples were kept in -180 °C and imaged with a JEM-2011 TEM (120 kV). Digital images were recorded in the minimal electron dose mode by a Gatan multi-scan cooled charge-coupled device (CCD) camera.

**Preparation of** *E. coli* solutions: A single colony of Amp<sup>r</sup> *E. coli* on a solid Luria Broth (LB) agar plate was transferred to 10 mL liquid LB culture medium with 50 µg/mL ampicillin and then was grown for 6 - 8 h at 37 °C under constant shaking of 180 rpm. *E. coli* was harvested by centrifuging (7100 rpm for 2 min) and was washed with PBS twice. After removal of the supernatant, the remaining *E. coli* was suspended in PBS and diluted to the optical density of 1.0 at 600 nm (OD<sub>600</sub> = 1.0).

Assessment of antibacterial activity: The antimicrobial activity of PAs to *E. coli* was evaluated using a traditional surface plating method.<sup>[1]</sup> Certain concentrations of PAs were separately added into *E. coli* solution and the mixtures were incubated for 30 min at 37 °C. Next, the *E. coli* suspensions were serially diluted 10<sup>4</sup>-fold with PBS. 100  $\mu$ L of the diluted *E. coli* was spread on the solid agar plate (LB) with 50  $\mu$ g/mL ampicillin, and *E. coli* colonies were counted after incubation for 14 – 16 h at 37 °C. The inhibition ratio (IR) was calculated according to the equation<sup>[2]</sup>

IR (%) = 
$$\frac{(A - B)}{B} \times 100$$

Where A is the mean number of *E. coli* colonies in the control sample (without PAs), and B is the mean number of *E. coli* after treated with the PAs. The diameter of the solid agar plates was 90 mm. The results were repeated three times.

**Scanning electron microscopy (SEM)**: The morphological changes of *E. coli* before and after the addition of different PAs were observed by SEM. After incubation of *E. coli* with PAs for 30 min, the mixture was centrifuged (7100 rpm for 5 min). The supernatant was removed, and the *E. coli* pellets were resuspended in sterile water. 2  $\mu$ L of *E. coli* suspensions were dropped onto clean silicon slices, followed by naturally drying in the super clean bench. After the specimens became dried, 0.1% glutaraldehyde was added to fixate for 1 h and then 0.5% glutaraldehyde for another 1 h. Next, the specimens were washed with sterile water three times, dehydrated by adding ethanol in a graded series (50% for 6 min, 70% for 6 min, 90% for 6 min, and 100% for 6 min), and then dried in a vacuum drying oven. Finally, the specimens were coated with platinum before SEM observation (Hitachi S4800).

**Confocal laser scanning microscopy (CLSM) characterization of membrane damage**: After treatment of *E. coli* with PAs for 30 min, the mixtures were centrifuged to obtain the *E. coli* pellets. The *E. coli* pellets ware then stained by two fluorescent nucleic acid stains: SYTO9 and propidium iodide according to the procedure. The samples were then examined by CLSM using a 488 nm laser for SYTO9 and 559 nm for PI.

**Zeta potential measurements**: *E. coli* was incubated by PAs of different concentrations at 37 °C for 30 min. Unbound PAs then were removed by centrifugation (7100 rpm, 5 min) at 4 °C. The pellets obtained were suspended in water and the suspensions were placed on ice for zeta potential measurements. Untreated *E. coli* (without PAs) was also incubated under the same conditions as the control.

**Isothermal titration microcalorimetry (ITC)**: The calorimetric measurements were conducted on a TAM III microcalorimeter system with a stainless steel sample cell of 1 mL at  $25.00 \pm 0.01$  °C. The sample cells were initially loaded with 750 µL PBS or *E. coli* PBS solution, and then the PA solution (40 µM 12-(Lys)<sub>2</sub>-12, 160 µM 12-(Lys)<sub>4</sub>-12, and 120 µM 12-(Lys)<sub>6</sub>-12, respectively) was injected consecutively into the stirred sample cell in portions of 10 µL via a 500 µL Hamilton syringe controlled by a 612 Thermometric Lund pump until the interaction progress was completed. The system was stirred at 60 rpm with a gold propeller. Each ITC curve was repeated at least twice with deviation within ± 4%. The dilution enthalpies of the PAs were subtracted from the corresponding observed enthalpy curve of the PAs with *E. coli*.

**Cytotoxicity assay**: HaCaT cells at a density of  $6 \times 10^3$  cells/well were seeded into 96-well culture plates and were grown for  $12 \sim 24$  h until adherence in a humified atmosphere containing 5% CO<sub>2</sub> and at 37 °C. Three PAs solutions of different concentrations were added into 96-well culture plates. After incubated for 24 h at 37 °C, the supernatant was removed and 100 µL 0.5 mg/mL MTT was added, and then incubated for 4 h at 37 °C. Subsequently, after removing the supernatant, 100 µL DMSO was added into well to dissolve the produced formazan. After shaking the plates for 2 min, absorbance values per wells at 520 nm were read by a microplate reader. The cell viability rate (VR) was calculated by the equation of

$$VR(\%) = \frac{A}{A_0} \times 100\%$$

Where A is the absorbance of the experimental groups with PAs and  $A_0$  is the absorbance of the control group without PAs. Each assay was repeated six times.

**MIC determination:** The MIC values of PAs  $12-(Lys)_2-12$ ,  $12-(Lys)_4-12$  and  $12-(Lys)_6-12$  were evaluated according to their dose-responsive fitting curves. The corresponding function of fitting curves as follows (y is antibacterial activity of PA and x is the concentration of PA).

$$y_{12-(Lys)2-12} = 5.23584 + \frac{94.74909}{1+10^{6.16406(1.28047 - \log x)}}$$
[1]

 $y_{12-(Lys)4-12} = 0.45742 + \frac{99.64515}{1+10^{5.00134(0.61743-logx)}}$ [2]

$$y_{12-(Lys)6-12} = -0.72658 + \frac{100.68176}{1+10^{2.58155(0.50435-logx)}}$$
[3]

MIC is defined as the concentration where 90% bacteria were killed. Therefore, when y is equal to 90%, the corresponding x value is MIC of PA ( $MIC_{12-(Lys)2-12} = 27.0 \ \mu M$ ,  $MIC_{12-(Lys)4-12} = 6.4 \ \mu M$  and  $MIC_{12-(Lys)6-12} = 7.5 \ \mu M$ ).

# **Supplementary Figures**




Figure S1. High-performance liquid chromatography of 12-(Lys)<sub>2</sub>-12.




Figure S2. <sup>1</sup>H NMR and ESI mass spectrum of 12-(Lys)<sub>2</sub>-12.




Figure S3. High-performance liquid chromatography of 12-(Lys)<sub>4</sub>-12.




Figure S4. <sup>1</sup>H NMR and ESI mass spectrum of 12-(Lys)<sub>4</sub>-12.







Figure S5. High-performance liquid chromatography of 12-(Lys)<sub>6</sub>-12.



**Figure S6**. <sup>1</sup>H NMR of and ESI mass spectrum of 12-(Lys)<sub>6</sub>-12.



**Figure S7.** Observed enthalpy changes ( $\Delta H_{obs}$ ) against the PAs/*E. coli* molar ratios by (a) titrating 40  $\mu$ M 12-(Lys)<sub>2</sub>-12 into OD = 0.15 *E. coli* solutions and (b) titrating 120  $\mu$ M 12-(Lys)<sub>6</sub>-12 into OD = 1 *E. coli* solutions. The dilution enthalpy of the PAs has been subtracted.



**Figure S8.** Zeta potential results of 12-(Lys)<sub>2</sub>-12, 12-(Lys)<sub>4</sub>-12, and 12-(Lys)<sub>6</sub>-12 in PBS solutions at different concentrations.

#### References

- [1] C. Xing, Q. Xu, H. Tang, L. Liu, S. Wang, J. Am. Chem. Soc. 2009, 131, 13117-13124.
- [2] S. Chen, S. Chen, S. Jiang, M. Xiong, J. Luo, J. Tang, Z. Ge, ACS Appl. Mater. Interfaces 2011, 3, 1154-1162.